Euclidean Capital LLC
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), Euclidean Capital LLC reported 10 stock positions worth $305.7 million. Its top holding was Vanguard Ftse All-World Ex-U (VEU) at 47.1% of the portfolio, followed by iShares MSCI India ETF (INDA, 44.2%) and Oric Pharmaceuticals (ORIC, 3.3%). Compared with Q1 2025, it opened 1 new position, sold out of 1 and added to 1. The biggest buy was Vanguard Ftse All-World Ex-U (VEU, shares +8%) and the biggest sale an exit from Rapt Therapeutics.
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001825034
- Portfolio Value
- $305.7M (Q2 2025)
- SEC Filing
- 0001012975-25-000445 ↗ filed Aug 14, 2025
Holdings Value
Holdings 10 stocks · $305.7M
| VEU Vanguard Ftse All-World Ex-U | 47.11% | 2,142,684 | $144.0M | Add +7.6% |
| INDA iShares MSCI India ETF | 44.17% | 2,425,144 | $135.0M | No change |
| ORIC Oric Pharmaceuticals Inc. | 3.28% | 989,410 | $10.0M | No change |
| FHTX Foghorn Therapeutics Inc. | 2.42% | 1,573,761 | $7.4M | No change |
| PMVP PMV Pharmaceuticals Inc. | 0.91% | 2,627,643 | $2.8M | No change |
| SPY SS SPDR S&P 500 ETF Trust-US | 0.83% | 4,104 | $2.5M | No change |
| ALEC Alector Inc. | 0.60% | 1,307,858 | $1.8M | No change |
| SRZN Surrozen Inc. | 0.26% | 87,696 | $784K | No change |
| RAPT Rapt Therapeutics Inc. | 0.22% | 82,234 | $658K | New |
| TNYA Tenaya Therapeutics Inc. | 0.20% | 1,015,705 | $621K | No change |
Other holdings (1): bonds, preferreds, convertibles and warrants · $3K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| SRZNW Surrozen Inc.-CW25 | *W EXP 08/01/203 | 170,833 | $3K | No change |
Total filed on the 13F, all lines: $305.7M.
Portfolio Sells Q1 2025 → Q2 2025
| RAPT THERAPEUTICS INC | Sold out | 0.00% | −0.30 |
Portfolio Buys Q1 2025 → Q2 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 10 | $439.8M | VEU, VTV, INDA, ORIC, TMS |
| Q1 2026 | 9 | $392.3M | VEU, VTV, INDA, ORIC, FHTX |
| Q4 2025 | 11 | $369.4M | VEU, VTV, INDA, FHTX, ORIC |
| Q3 2025 | 10 | $238.0M | VEU, INDA, ORIC, FHTX, ALEC |
| Q2 2025 | 10 | $305.7M | VEU, INDA, ORIC, FHTX, PMVP |
| Q1 2025 | 10 | $266.1M | INDA, VEU, FHTX, ORIC, PMVP |
| Q4 2024 | 10 | $736.7M | SPY, INDA, VEU, ORIC, FHTX |
| Q3 2024 | 11 | $906.8M | SPY, INDA, VEU, FHTX, ORIC |
| Q2 2024 | 10 | $795.8M | SPY, INDA, FHTX, ORIC, ALEC |
| Q1 2024 | 12 | $780.0M | SPY, INDA, GLD, ORIC, FHTX |